
MARCH 2015 QUARTERLY CASH FLOW REPORT

3D Medical Limited (ASX: **3DM**) today released its quarterly cash flow report for the period ended 31 March 2015.

Commentary

Net operating cash outflow for the March 2015 quarter was \$323,000 with a further \$460,000 in cash outflow relating to non-recurring expenses associated with capital raising and corporate advisory services from the transaction between Safety Medical Products and 3D Medical.

During the period, the first partial quarter as an ASX listed entity, the Company completed sales to 11 new clients. Many of these purchases were effectively reference sales of 3D printed anatomical models to confirm the quality of printing and after sales service offered by 3DM. Receipts for the majority of these purchases will flow in the June 2015 quarter.

The Company is primarily focussed on increasing the volume of sales from these customers and increasing the number of customers that it services. In support of this objective 3DM signed an exclusive supply agreement with the Australian Cranio-Maxillo Facial Foundation during the period.

In addition to the sale of 3D anatomical models, 3DM is the exclusive distributor of EchoPixel Inc.'s True3D Viewer which uses holographic technology to display 3D imagery in a clinical setting. EchoPixel Inc. received FDA 510 (K) clearance approval for their product in March. In the quarter, 3DM placed the first True3D viewer in an Australian research institution and is in discussions with a number of other potential end users.

The Company continues dialogue regarding a distribution relationship with Telstra Health for the Mach7 Technologies Vendor Neutral Archive technology. 3DM has secured its first client for the product with revenues expected to flow from September 2015 quarter.

In reviewing the company's liquidity and cash flow, the directors note that the Company:

- (a) anticipates sales and licensing receipts from customers over the coming months; and
- (b) holds a cash balance of \$3.535 million as at 31 March 2015

END**For more information:**

3D Medical Limited
Max Ghobrial CEO (+61 3 9646 2222)
Email: info@3dmedical.com.au
Web: www.3dmedical.com.au

About 3D Medical Limited:

ASX Announcement

30 April 2015

At 3D Medical our aim is to aid medical professionals in the facilitation of improved clinical care, improving medical procedures, diagnostics and ultimately improving patient outcomes.

3D Medical is a medical specific 3D printing and holographic projection and data integrations provider. Our services 3D Medical Printing; EchoPixel (holographic projection technology); Mach 7 (enterprise imaging solution provides healthcare organisations with the ability to archive, consolidate, access, and share medical imaging data across departments, locations and regions) and MediDATA service provides medical practices the opportunity to leverage their analytical capabilities to gain an improved understanding of the characteristics of the patients which drive their business.

These new and innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes.

Further information is available at www.3dmedical.com.au

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

3D Medical Limited

ABN

26 007 817 192

Quarter ended ("current quarter")

31 March 2015

Consolidated statement of cash flows

The March 2015 Appendix 4C represents cashflows for the 9 months to March 2015 in relation to operations conducted by 3D Medical Limited, plus cashflows following the reverse takeover transaction completed on 6th February 2015 to the end of the March 2015 quarter for business associated with Safety Medical Products Ltd. The cashflow report does not represent the former business operations of Safety Medical Products Limited reported in the December 2014 cashflow report.

Cash flows related to operating activities		Current quarter \$A'000	Year to date (9 months) \$A'000
1.1	Receipts from customers	29	106
1.2	Payments for (a) staff costs	(118)	(238)
	(b) advertising & marketing	(12)	(16)
	(c) research & development	-	-
	(d) leased assets	-	-
	(e) other working capital	(229)	(610)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	7	10
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other (provide details if material)	-	6
Net operating cash flows		(323)	(742)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (9 months) \$A'000
1.8 Net operating cash flows (carried forward)	(323)	(742)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(15)	(171)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities.	-	-
1.12 Loans repaid by other entities.	-	-
1.13 Other – Acquisition costs.	(178)	(178)
Other – Cash acquired on completion of transaction with Safety Medical Products Ltd.	2,285	2,285
Net investing cash flows	2,092	1,936
1.14 Total operating and investing cash flows	1,769	1,194
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	1,870	1,915
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	610
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other – Capital raising costs	(282)	(392)
Net financing cash flows	1,588	2,133
Net increase (decrease) in cash held	3,357	3,327
1.21 Cash at beginning of quarter/year to date	178	208
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	3,535	3,535

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

	Current quarter \$A'000
1.24 Aggregate amount of payments to the parties included in item 1.2	98
1.25 Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

1. Director fees;
2. Accounting, company secretarial and office services;
3. Legal fees; and
4. Capital raising fees.
5. Corporate advisory fees.
6. Re-imbursement of operating costs.

Includes amounts paid to entities associated with the Directors.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

On 6 February 2015, the following shares and options were issued:

- 175,000,000 ordinary shares and 116,431,447 options were issued to shareholders as consideration for the acquisition of 3D Medical Limited.
- 8,750,000 ordinary shares were issued as consideration for facilitation/advisory fees.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Safety Medical Products Ltd acquired the business of 3D Medical Limited via a reverse takeover transaction that was completed on 6th February 2015. 175,000,000 ordinary shares and 116,431,447 options were issued to shareholders of 3D Medical Limited as consideration for the acquisition of 3D Medical Limited. The Company changed its name and 3D Medical Limited (ASX:3DM) shares were reinstated for quotation on 18th February 2015.

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	3,491	134
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other – Lease Bond	44	44
Total: cash at end of quarter (item 1.23)	3,535	178

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Safety Medical Products Ltd acquired all shares in 3D Medical Limited as part of a reverse takeover transaction completed on 6th February 2015.	-
5.2 Place of incorporation or registration	Victoria, Australia.	-
5.3 Consideration for acquisition or disposal	175,000,000 Ordinary Shares and 116,431,447 Options	-
5.4 Total net assets	\$213,779	-
5.5 Nature of business	The provision of medical specific 3D printing and holographic projection.	-

Compliance statement

- This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- This statement does give a true and fair view of the matters disclosed.

Sign here:
(Company Secretary)

Date: 30th April 2015

Print name: Andrew Metcalfe

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.